公司宣布日本将补助Impella®心脏泵,并上调2018财年的收入预报下限
本财年第1季度来自Impella®心脏泵的全球收入总计为1.272亿美元,较上个财年同期收入9,780万美元增长30%。来自Impella心脏泵的美国收入增长28%,为1.147亿美元,并且美国Impella患者使用率增长27%。
在美国境外,Impella心脏泵的收入总计为1,250万美元,增长53%,其中主要来自德国,其收入较上个财年增长62%。
在美国,Impella 2.5®心脏泵的安装基数额外增加16间医院。这些医院首次购买Impella心脏泵,使客户安装点基数达到1,154个。Impella CP®心脏泵的客户安装基数新增46间美国医院,使Impella CP安装点总数达到1,062个。Impella 5.0®心脏泵的客户安装基数新增19间美国医院,使Impella 5.0安装点总数达到472个。
另外15个安装点在本季度首次购买Impella RP®心脏泵,使安装点总数达到142个。
2018财年第1季度的毛利率为83.5%,而2017财年第1季度则为85.4%。
2018财年第1季度的营业收入为3,310万美元,经营毛利率为25.0%,而去年同期的营业收入则为2,120万美元,经营毛利率为20.6%。
受益于采纳新会计准则,2018财年第1季度的GAAP纯利为3,740万美元或每股摊薄股份0.82美元。新会计准则要求录入与员工股份薪酬奖励相关的超额税务利益1,680万美元或每股摊薄股份0.37美元,从而减少所得税开支。去年同期,采纳新会计准则之前的GAAP纯利为1,290万美元或每股摊薄股份0.29美元。
公司产生1,200万美元的现金、现金等价物及有价证券,截至2017年6月30日的总额为2.891亿美元,而2017年3月31日则为2.771亿美元。公司在第1季度有年度现金支出,不过目前没有负债。
公司最近收到了日本厚生劳动省(MHLW)就Impella 2.5和5.0 Impella心脏泵发出的补助批准,10个医师学会已经完成了医院指引文件。按照最近的平均汇率,日本的偿付金额估计为24,000美元,相当于Impella在美国的售价,并且在今年9月份开始支付。我们预计将在9月份迎来我们的首位日本患者,并且重申我们将会顺利于3月份的财年底之前于限有的10间医院推出我们的Impella。
在6月30日,一项有关Abiomed的Impella 2.5心脏泵的新研究证明指出,伴随经皮冠状动脉介入治疗(PCI),可能会提高左主干冠状动脉心脏病发作的存活机率。
Abiomed, Inc. and Subsidiaries | ||||||||||||||||
Consolidated Balance Sheets | ||||||||||||||||
(Unaudited) | ||||||||||||||||
(in thousands, except share data) | ||||||||||||||||
June 30, 2017 | March 31, 2017 | |||||||||||||||
ASSETS | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash and cash equivalents | $ | 43,970 | $ | 39,040 | ||||||||||||
Short-term marketable securities | 207,441 | 190,908 | ||||||||||||||
Accounts receivable, net | 53,557 | 54,055 | ||||||||||||||
Inventories | 36,926 | 34,931 | ||||||||||||||
Prepaid expenses and other current assets | 9,021 | 8,024 | ||||||||||||||
Total current assets | 350,915 | 326,958 | ||||||||||||||
Long-term marketable securities | 37,669 | 47,143 | ||||||||||||||
Property and equipment, net | 92,804 | 87,777 | ||||||||||||||
Goodwill | 33,199 | 31,045 | ||||||||||||||
In-process research and development | 15,487 | 14,482 | ||||||||||||||
Long-term deferred tax assets, net | 113,457 | 34,723 | ||||||||||||||
Other assets | 8,686 | 8,286 | ||||||||||||||
Total assets | $ | 652,217 | $ | 550,414 | ||||||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Accounts payable | $ | 12,784 | $ | 20,620 | ||||||||||||
Accrued expenses | 35,695 | 37,703 | ||||||||||||||
Deferred revenue | 9,697 | 10,495 | ||||||||||||||
Current portion of capital lease obligation | 829 | 799 | ||||||||||||||
Total current liabilities | 59,005 | 69,617 | ||||||||||||||
Other long-term liabilities | 588 | 3,251 | ||||||||||||||
Contingent consideration | 9,418 | 9,153 | ||||||||||||||
Long-term deferred tax liabilities | 837 | 783 | ||||||||||||||
Capital lease obligation, net of current portion | 15,325 | 15,539 | ||||||||||||||
Total liabilities | 85,173 | 98,343 | ||||||||||||||
Commitments and contingencies | ||||||||||||||||
Stockholders' equity: | ||||||||||||||||
Class B Preferred Stock, $.01 par value | — | — | ||||||||||||||
Authorized - 1,000,000 shares; Issued and outstanding - none | ||||||||||||||||
Common stock, $.01 par value | 441 | 437 | ||||||||||||||
Authorized - 100,000,000 shares; Issued - 45,791,680 shares at June 30, 2017 and 45,249,281 shares at March 31, 2017 | ||||||||||||||||
Outstanding - 44,080,941 shares at June 30, 2017 and 43,673,286 shares at March 31, 2017 | ||||||||||||||||
Additional paid in capital | 580,017 | 565,962 | ||||||||||||||
Retained earnings (accumulated deficit) | 65,661 | (46,959 | ) | |||||||||||||
Treasury stock at cost - 1,710,739 shares at June 30, 2017 and 1,575,995 shares at March 31, 2017 | (64,567 | ) | (46,763 | ) | ||||||||||||
Accumulated other comprehensive loss | (14,508 | ) | (20,606 | ) | ||||||||||||
Total stockholders' equity | 567,044 | 452,071 | ||||||||||||||
Total liabilities and stockholders' equity | $ | 652,217 | $ | 550,414 | ||||||||||||
Abiomed, Inc. and Subsidiaries | ||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||
(Unaudited) | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
Three Months Ended June 30, |
||||||||||||||||
2017 | 2016 | |||||||||||||||
Revenue: | ||||||||||||||||
Product revenue | $ | 132,431 | $ | 102,989 | ||||||||||||
Funded research and development | 37 | 6 | ||||||||||||||
132,468 | 102,995 | |||||||||||||||
Costs and expenses: | ||||||||||||||||
Cost of product revenue | 21,862 | 15,070 | ||||||||||||||
Research and development | 16,931 | 15,660 | ||||||||||||||
Selling, general and administrative | 60,597 | 51,032 | ||||||||||||||
99,390 | 81,762 | |||||||||||||||
Income from operations | 33,078 | 21,233 | ||||||||||||||
Other income: | ||||||||||||||||
Investment income, net | 635 | 269 | ||||||||||||||
Other income (expense), net | 79 | (77 | ) | |||||||||||||
714 | 192 | |||||||||||||||
Income before income taxes | 33,792 | 21,425 | ||||||||||||||
Income tax (benefit) provision (1) | (3,582 | ) | 8,515 | |||||||||||||
Net income | $ | 37,374 | $ | 12,910 | ||||||||||||
Basic net income per share | $ | 0.85 | $ | 0.30 | ||||||||||||
Basic weighted average shares outstanding | 43,895 | 42,811 | ||||||||||||||
Diluted net income per share (2) | $ | 0.82 | $ | 0.29 | ||||||||||||
Diluted weighted average shares outstanding | 45,608 | 45,178 | ||||||||||||||
(1) Income tax provision includes the effect of the following item: | ||||||||||||||||
Excess tax benefits related to stock-based compensation awards * | $ | 16,842 | $ | — | ||||||||||||
(2) Diluted net income per share includes the effect of the following item: | ||||||||||||||||
Excess tax benefits related to stock-based compensation awards * | $ | 0.37 | $ | — | ||||||||||||
* In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required. | ||||||||||||||||
欲了解更多信息,请联系: Ingrid Goldberg Ward 投资者关系部总监 978-646-1590 ir@abiomed.com Adrienne Smith 公共关系和企业传讯部高级总监 978-646-1553 adsmith@abiomed.com
新闻热点
新闻爆料